This is the authors' abstract. We don't add key points for this paper.
Molecular changes in prostate cancer lead to increased expression of prostate-specific membrane antigen (PSMA), which is a suitable target for imaging and therapy using radiopharmaceuticals. Data on the most effective clinically significant PSMA radiopharmaceuticals for the diagnosis and treatment of prostate cancer are summarized. The advantages and disadvantages of ligands based on monoclonal antibodies and their fragments as well as small molecular PSMA inhibitors are discussed.
No takes yet. Share an insight, caveat, or question.
Тищенко et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: